Research progress of cellular immune function in patients with hepatocellular carcinoma after operation
10.3760/cma.j.cn115396-20200512-00146
- VernacularTitle:肝细胞肝癌患者术后细胞免疫功能变化的研究进展
- Author:
Zhe JIA
1
;
Ke ZHANG
;
Ronghai HUANG
;
Rong HE
;
Yan LU
;
Li JIANG
Author Information
1. 首都医科大学附属北京地坛医院普外科 100015
- From:
International Journal of Surgery
2020;47(10):697-702
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immunotherapy for hepatocellular carcinoma has gradually become a hot spot in clinical research. The characteristic of its immunotherapy is to stimulate specific immune response, enhance the immune rejection of tumors, inhibit and kill tumor cells, thereby reducing the possibility of tumor recurrence and metastasis. A large number of previous experimental studies have shown that immunotherapy has the potential advantages of monotherapy or combination therapy in the treatment of primary liver cancer. As we all know, whether it is to kill tumor cells in the short term or to control tumor recurrence in the long term, the necessary condition for immune drugs to work is a healthy immune environment. This article reviews the immune microenvironment in patients with liver cancer and the changes in the tumor immune microenvironment after various operations or treatments. It provides references for exploring mutually synergistic treatment plans for liver cancer, and hopes to help improve the prognosis of these patients.
